INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Amortized intangible assets:
Acquired finite-lived intangible assets, weighted average useful life	10 years 10 months 24 days
Gross Carrying Value	$ 547,176		$ 460,875
Carrying value	141,440		224,240
Amortization of Intangible Assets	8,800	$ 4,300
Goodwill	208,382		210,166
Minimum
Expected Amortization Expense
2016	37,800
2017	37,800
2018	37,800
2019	37,800
2020	37,800
Maximum
Expected Amortization Expense
2016	59,100
2017	59,100
2018	59,100
2019	59,100
2020	59,100
Impax Generics
Amortized intangible assets:
Goodwill	148,700
Impax Specialty Pharma
Amortized intangible assets:
Goodwill	59,700
Teva
Amortized intangible assets:
Milestone payment, capitalized	3,500
Marketed Product Rights
Amortized intangible assets:
Gross Carrying Value	544,976		458,675
Marketed Product Rights | EMVERM
Amortized intangible assets:
Gross Carrying Value	$ 86,300
In-process research and development
Amortized intangible assets:
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure			82,800
In-process research and development | EMVERM
Amortized intangible assets:
Carrying value			$ 82,800